mRNA will be crucial to beating cancer and solving disease but only if we can deliver it to the right cells.
Nanograb's AI-designed multivalent nanoparticles address a cell's unique receptor fingerprint, now proven in vivo across multiple cell types and scaling to many more.
Multivalent superselectivity is just the tip of the iceberg when it comes to designing targeted LNPs but it's an area of biophysics we are extremely excited about.
Read the full piece and subscribe!
superselectivity.substack.co…
When @nanograb designs peptides for delivering mRNA via targeted LNPs, we tune for the amounts of a given receptor on a cell, not just its presence.
Multivalent superselectivity helps us achieve this level of targeting. Read more in our new substack! (link below)
every once in a while, a company actually has a useful update that I'd like to know about, but things have been way too messy / low value in the email channel for a long time
it would be useful to have a new version of the marketing newsletter / changelog / RSS feed for agents
I set my AI thing to subscribe to your feed, and it decides what gets through to me / whether your information is high-quality enough to justify continued subscription
would use extensively
It’s getting popular to build autonomous labs to scale up biological data generation 24/7, but focusing automation on well-established in vitro assays with existing hardware risks solving the easiest least painful step, rather than the problems that matter the most for drug discovery.
One analogy is like generating decades of closed-course driving data with hopes of training self-driving cars that can navigate Manhattan.
I think the most valuable data from autonomous labs will come at the intersection of novel assay technologies with valuable samples - often complex animal models, organoids, primary tissue, not immortalized cancer cell lines. Not that more complexity in the assay/model system is always better, but scaling existing assays 1000x won’t overcome the fundamental limits of what they can measure. Training AI models to find drugs that existing approaches have failed to discover will probably require generating types of data that existing technologies cannot generate.
Teams building the next generation of autonomous labs need to have the skillsets to (i) invent new & uniquely valuable assay technologies & (ii) invent the custom hardware to automate them.
Because it's a single crystal, the blade doesn't "creep" over time at high temps. If a trad alloy was used then the blade would slowly extend over time at high temps and smash through the inside of the engine
🙄 US is not 80% of the furniture market. We are 80% of the drug market, these comparisons aren’t relevant. No other private industry is like drugs because drug pricing is so skewed to the US market. USG controls this industry so they can get drugs developed wherever they want.
🚨😜In this video, Nvidia CEO Jensen Huang and Nvidia VP Kimberly Powell are seen dancing in a very fun manner.
Some people say that Kimberly Powell got pregnant on this day in the bedroom.
@Grok Confirm it
ditto. many biotechs complain about time and data quality. the fact that the founders themselves don't have years of experience at CROs doesn't mean they can't hire scientists that do. execution is not a moat.
the field almost univocally agrees there's need for more data. existing CROs don't seem to have the capacity to serve the entire market.
Today we are launching @BioDelivera a programmable drug delivery platform that delivers therapies only to diseased cells enabling cures for every disease. 🎯🧪
Less than 3% of an injected therapy reaches diseased cells. The rest ends up in healthy organs. At @BioDelivera we want to change that, our mission is to make every therapy accessible to patients.
Happy to build with @ikeda_trashi this exciting technology!
Reach out at founders@biodelivera.com
Building @numenbio with @_tom_dot_com to engineer a future without cancer deaths. Find out more below in an interview with our partners at @TQVentures!
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.
What it actually takes to build it:
“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”
@luca_springer, co-founder and CEO of @numenbio
Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem
We are at the beginning of a new and exciting era to be able to program our immune system in the body (in vivo). This new review @SciImmunology nails it science.org/doi/10.1126/scii…
We're excited to unveil VINCO, our frontier AI model trained to play and win 1v1 Catan.
We've secretly deployed it on the Colonist.io global leaderboard, where it has reached both the #1 and #2 positions, consistently beating every human world champion.